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Abstract
Background: Leukocyte telomere length, an emerging marker of biological age, has been shown to predict cardiovascular
morbidity and mortality. However, the natural history of telomere length in patients with coronary artery disease has not
been studied. We sought to investigate the longitudinal trajectory of telomere length, and to identify the independent
predictors of telomere shortening, in persons with coronary artery disease.
Methodology/Principal Findings: In a prospective cohort study of 608 individuals with stable coronary artery disease, we
measured leukocyte telomere length at baseline, and again after five years of follow-up. We used multivariable linear and
logistic regression models to identify the independent predictors of leukocyte telomere trajectory. Baseline and follow-up
telomere lengths were normally distributed. Mean telomere length decreased by 42 base pairs per year (p,0.001). Three
distinct telomere trajectories were observed: shortening in 45%, maintenance in 32%, and lengthening in 23% of
participants. The most powerful predictor of telomere shortening was baseline telomere length (OR per SD increase = 7.6;
95% CI 5.5, 10.6). Other independent predictors of telomere shortening were age (OR per 10 years = 1.6; 95% CI 1.3, 2.1),
male sex (OR = 2.4; 95% CI 1.3, 4.7), and waist-to-hip ratio (OR per 0.1 increase = 1.4; 95% CI 1.0, 2.0).
Conclusions/Significance: Leukocyte telomere length may increase as well as decrease in persons with coronary artery
disease. Telomere length trajectory is powerfully influenced by baseline telomere length, possibly suggesting negative
feedback regulation. Age, male sex, and abdominal obesity independently predict telomere shortening. The mechanisms
and reversibility of telomeric aging in cardiovascular disease deserve further study.
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Introduction
Telomeres are tandem repeat DNA sequences (TTAGGG)n
which form a protective cap at the ends of eukaryotic
chromosomes[1]. During somatic cell division, DNA polymerase
cannot fully replicate the 39 end of linear DNA, thus resulting in
an obligate and progressive loss of telomeric repeats[2]. After a
critical degree of telomere shortening, cells lose the ability to
replicate and may cease dividing (senescence) or undergo
programmed cell death[3]. Human telomere length is influenced
by both genetic and environmental factors[4]. These fundamental
observations have led to increasing interest in telomere length as
the possible basis for a ‘‘biological clock’’ which integrates the
cumulative lifetime burden of genetic factors and environmental
stressors independently of chronological age[5].
A growing body of evidence has demonstrated an independent
association between short telomere length and cardiovascular
events, including myocardial infarction[6,7], congestive heart
failure[8], and death[9,10]. In addition, several large epidemio-
logic studies have demonstrated cross-sectional associations
of short telomeres with risk factors for coronary artery
disease[11,12,13]. However, the natural history of telomere
length, and the determinants of temporal change in telomere
length in persons with established cardiovascular disease, have not
previously been investigated.
We sought to evaluate the trajectory of change in leukocyte
telomere length, and to identify the demographic, clinical and
biochemical predictors of telomere trajectory, in a prospective
cohort study of patients with stable coronary artery disease. In
particular, we aimed to detect modifiable risk factors, which
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influence telomere length over time, and which may lead to novel
insights into the mechanisms of biological aging.
Methods
Participants
The Heart and Soul Study is a prospective cohort study
investigating the influence of psychosocial factors on cardiovascu-
lar events in stable coronary artery disease. The enrollment
process has been previously described[14]. Eligible participants
were recruited from outpatient clinics in the San Francisco Bay
Area if they met at least one of the following inclusion criteria: 1)
history of myocardial infarction, 2) angiographic evidence of at
least 50% stenosis by area in at least one coronary artery, 3)
evidence of exercise-induced ischemia by treadmill electrocardio-
gram or stress nuclear perfusion imaging, or 4) history of coronary
revascularization. Individuals were excluded if they had a history
of myocardial infarction in the past 6 months, deemed themselves
unable to walk 1 block, or if they were planning to move out of the
local area within 3 years.
The study protocol was approved by: the University of
California San Francisco Committee on Human Research, the
Research and Development Committee at the San Francisco VA
Medical Center, the Medical Human Subjects Committee at
Stanford University, the Human Subjects Committee at the VA
Palo Alto Health Care System, and the Data governance Board of
the Community Health Network of San Francisco. All participants
provided written informed consent. Between September 2000 and
December 2002, a total of 1024 participants enrolled in the study.
Of these, 954 provided DNA samples for analysis at the baseline
visit, and 608 also provided DNA samples after 5 years of
follow-up.
Telomere Length Assay
Blood samples collected from participants at baseline and
follow-up visits were subjected to density gradient centrifugation to
yield a buffy coat preparation containing peripheral blood
leukocytes and stored at 270C. Genomic DNA was isolated
according to standard procedures using the Wizard Genomic
DNA Purification Kit (Promega Corp, Madison WI). Purified
DNA samples were diluted in 96-well microtiter source plates to a
fixed concentration of 3 ng/ul. Relative mean telomere length was
measured from DNA by a quantitative polymerase chain reaction
(qPCR) assay that compares mean telomere repeat sequence copy
number (T) to a reference single copy gene copy number (S) in
each sample as previously described and validated by comparison
with Southern blot terminal restriction fragment (TRF) analy-
sis[15]. Standard curves were derived from serially diluted
reference DNA. The T/S ratio was determined from the average
quantity of reference DNA found to match with each experimental
sample for the copy number of the targeted template (the number
of telomere repeats for T and the number of beta-globin gene
copies for S).
The primers for the telomere qPCR were tel1b [59-CGGT-
TT(GTTTGG)5GTT-39] and tel2b [59-GGCTTG(CCTTAC)5-
CCT-39], each used at a final concentration of 900 nM. Human
beta-globin qPCR primers were: hbg1 [59-GCTTCTGACA-
CAACTGTGTTCACTAGC-39], used at a final concentration
of 300 nM, and hbg2 [59-CACCAACTTCATCCACGTTCA-
CC-39], used at a final concentration of 700 nM. The final
reaction mix was: 20 mM Tris–HCl, pH 8.4; 50 mM KCl;
200 nM each dNTP; 1% DMSO; 0.46Sybr Green I; 44 ng
Escherichia coli DNA; 0.8 U Platinum Taq DNA polymerase
(Invitrogen) per 11 ml reaction; 10 ng genomic DNA. All PCRs
were carried out on a Roche Lightcycler 480 real-time PCR
machine (Roche Applied Science, Indianopolis, IN).
To control for inter-assay variability, eight control DNA
samples were included in each run. The T/S ratio of each control
DNA was divided by the average T/S for the same DNA from
each run to obtain a normalizing factor. The average normalizing
factor across all eight samples was then used to adjust the
participant DNA measurements to obtain the final T/S ratios in
each batch. The coefficient of variability for the eight control
samples across all batches was 6%. The T/S ratio at baseline and
follow-up for each participant was measured in duplicate. When
the duplicate T/S value and the initial value varied by more than
7%, the sample was run for a third time, and the two closest values
were used. Approximately 15% of samples required assay in
triplicate. Using this method, the inter-assay coefficient of
variability for telomere length measurement was 3.7% (equivalent
to 0.20 kilobases with respect to the baseline mean). The intra-
assay coefficient of variability was 2.5% (equivalent to 0.13
kilobases with respect to the baseline mean).
To determine the conversion factor for the calculation of
approximate base pair telomere length from T/S ratio, the above
method was used to determine the T/S ratios, relative to the same
reference DNA, for a set of genomic DNA samples from the
human fibroblast primary cell line IMR90 at different population
doublings, as well as with the telomerase protein subunit gene
(hTERT) transfected into a lentiviral construct. The mean TRF
length from these DNA samples was determined using Southern
blot analysis, and the slope of the plot of mean TRF length versus
T/S for these samples served as the conversion factor for
calculation of telomere length in base pairs from the T/S ratio.
The equation for conversion from T/S ratio to base pairs for this
study was base pairs = 3274+2413*(T/S).
Measurement of leukocyte telomere length was performed in a
blinded fashion without knowledge of the clinical data.
Other Measurements
Baseline demographics, age, sex, and self-reported ethnicity,
education, and income level were obtained by questionnaire.
Cardiovascular co-morbidities and prior medical history were
determined by self-report. Medication use was determined by
having participants bring bottles to the study appointment during
which study personnel recorded all medications. Participants were
weighed and measured without shoes. Waist and hip circumfer-
ences were measured with a flexible plastic measure to the nearest
0.1-centimeter. Waist circumference was measured midway
between the lower rib margin and iliac crest. Hip circumference
was measured at the level of the greater trochanters. Waist-to-hip
ratio was calculated as waist circumference divided by hip
circumference. Body mass index was calculated as weight in
kilograms divided by height squared in meters. Physical activity,
defined as a dichotomous predictor (active versus inactive), was
determined by questionnaire. Exercise capacity was measured at
peak exertion during a symptom-limited exercise-treadmill stress
test as previously described[16].
All patients underwent complete resting 2-dimensional echo-
cardiography and Doppler examination using an Acuson Sequoia
ultrasound system (Siemens Medical Solutions, Mountain View,
CA) with a 3.5-MHz transducer. The left ventricular ejection
fraction (LVEF) was calculated as (end diastolic volume – end
systolic volume)/end diastolic volume.
Fasting venous blood samples were obtained at the baseline visit
to measure serum biomarkers. Fasting glucose, HDL- and LDL-
cholesterol levels, and C-reactive protein (CRP) were measured in
a clinical laboratory setting. CRP was measured using the Roche
Telomere Length Trajectory
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Integra high-sensitivity assay (Roche, Indianapolis, Indiana) in 229
participants and (due to a change in the laboratory) the Beckman
Extended Range high-sensitivity CRP assay (Beckman, Galway,
Ireland) in the remaining participants. We used the ‘‘Human
Serum Adipokine Panel A’’ immunoassay to measure adiponectin,
and the ‘‘Human Serum Adipokine Panel B’’ to measure leptin,
TNF alpha, and insulin (LINCOplexH system; Millipore, St
Charles, MO). The R&D Systems (Minneapolis, MN) Quantikine
HS IL-6 Immunoassay was used to determine the concentration
of IL-6.
Statistical Analyses
Baseline and follow-up telomere lengths were normally
distributed. Continuous variables with a skewed distribution were
natural logarithm transformed prior to further analysis. We
categorized leukocyte telomere trajectory into three groups:
shortened (defined as .10% decrease in telomere length),
maintained (defined as 610% change in telomere length), and
lengthened (defined as .10% increase in telomere length).
Differences in means and proportions of baseline characteristics
by telomere trajectory were compared with the use of analysis of
variance and the chi-squared test respectively. All p-values were
two-tailed.
To identify the independent predictors of leukocyte telomere
trajectory, we used multivariable linear regression with stepwise
backward selection of candidate variables in Table 1. These
predictors were chosen a priori based on reported cross-sectional
associations with telomere length, biological plausibility, and
established cardiovascular risk factors. Covariate selection was
checked by visual inspection of directed acyclic graphs[17].
Variables were retained in the model at a significance level of
p,0.1. Age, sex, ethnicity, and LVEF were retained in all models
for face validity. For all linear regression models, the assumption of
linearity was checked by visual inspection of component plus
residual plots. The incremental contributions of polynomial terms
in the predictors were evaluated by the likelihood ratio test. The
normality assumption was checked by review of residual
histograms and normal quantile-quantile plots. In order to identify
mediating factors that may account for the observed associations
of waist-to-hip ratio with telomere trajectory, we forced body mass
index, adipokine levels and biomarkers of systemic inflammation
back into the linear regression models.
We then used multivariable logistic regression models to identify
the independent predictors of leukocyte telomere shortening (vs.
maintained or lengthened) as a dichotomous variable, again using
a stepwise backward selection strategy with predictors retained in
the final model at p,0.1. Model adequacy was confirmed using
the Hosmer-Lemeshow goodness of fit test. Statistical analysis was
performed using Intercooled STATA 10.0 (STATA Corporation,
College Station, TX). The authors take responsibility for the
integrity of the data. All authors had full access to the data, and
have read and agree to the manuscript as written.
Results
Baseline telomere length, follow-up telomere length, and change
in telomere length were all normally distributed (Figures 1 and
2). The mean (6SD) leukocyte telomere length at baseline was
5496 (6528) base pairs. The mean (6SD) leukocyte telomere
length after 5 years of follow-up was 5286 (6355) base pairs. The
mean telomere length decreased by 42 base pairs per year
(p,0.001). Overall, telomere shortening was observed in 45% of
participants; telomere maintenance was observed in 32% of
participants; and telomere lengthening was observed in 23%
of participants. Hence we use the term telomere trajectory to
emphasize that leukocyte telomere length in humans does not
inevitably decrease over time.
The characteristics of the study population categorized by
leukocyte telomere trajectory are shown in Table 1. In unadjusted
bivariate analyses, participants whose telomeres shortened were
more likely to be male, had longer baseline telomere length,
greater waist-to-hip ratio, higher prevalence of prior revascular-
ization, and more multivitamin use than participants whose
telomere length was maintained or increased. There were no
significant differences in ethnicity, education, income level, body
mass index, co-morbidities, or smoking across categories of
telomere trajectory.
The independent predictors of change in leukocyte telomere
length retained in the final linear regression model were: baseline
telomere length (T/S), the square of baseline telomere length (T/
S) 2, age, male sex, and waist-to-hip ratio. The beta-coefficients
and corresponding 95% confidence intervals for each independent
predictor are summarized in Table 2. The inverse association of
change in telomere length with baseline telomere length is
illustrated in Figure 3.
The independent predictors of leukocyte telomere shortening
retained in the final logistic regression model were: baseline
telomere length (T/S) (OR per SD=7.6; 95% CI 5.5, 10.6), age
(OR per 10 year increase = 1.6; 95% CI 1.3, 2.1), male sex
(OR=2.4; 95% CI 1.3, 4.7), and waist-to-hip ratio (OR per 0.1
increase = 1.4; 95% CI 1.0, 2.0). The odds ratios and correspond-
ing 95% confidence intervals for each independent predictor are
summarized in Table 3.
With body mass index, adipokines, and mediators of systemic
inflammation forced into a multivariable linear regression model
with waist-to-hip ratio, we observed no significant attenuation of
the effect of abdominal obesity on telomere shortening (Table 4).
Discussion
In this longitudinal study of 608 patients with stable coronary
artery disease, we observed three distinct telomere trajectories:
45% exhibited telomere shortening, 32% maintained the same
telomere length, and 23% lengthened their telomeres during 5
years of follow-up. We also identified four independent predictors
of telomere shortening in patients with coronary artery disease:
longer baseline telomere length, older age, male sex, and higher
waist to hip ratio. These observations suggest bidirectional
regulation of leukocyte telomere length, and raise the possibility
that telomeric aging may be reversed.
Prior studies have observed telomere lengthening in approxi-
mately 12–24% of healthy individuals [18,19], but the trajectory of
telomere length has not previously been evaluated in patients with
coronary artery disease. Given the physiological burden of chronic
illness, one might expect telomere shortening to occur in a greater
proportion of patients with coronary artery disease. However, less
than half of our sample experienced telomere shortening, and
almost a quarter actually lengthened their telomeres during the 5-
year follow-up. Moreover, individuals with the longest telomeres
experienced the greatest amount of shortening, while those with
shorter telomeres either maintained or increased their length.
These results demonstrate for the first time that the inverse
association previously seen in healthy individuals [18,19,20]
extends to patients with coronary artery disease. Consistent with
mathematical models of telomere shortening [21], these observa-
tions further suggest that there may be negative feedback
regulation of leukocyte telomere length in humans. An intriguing
candidate for mediating such regulation is the enzyme telomerase,
Telomere Length Trajectory
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which is active in hematopoietic stem and progenitor cells, and at
low levels in peripheral blood leukocytes [22].
Surprisingly, once baseline telomere length was taken into
consideration, only a few other candidate variables retained an
independent effect on telomere trajectory. Specifically, and in
contrast with prior cross-sectional studies [12,13,23,24,25,26,27],
we found no significant associations between telomere trajec-
tory and ethnicity, socioeconomic status, blood pressure, insulin
resistance, smoking, body mass index, physical activity, or
consumption of multivitamins. These findings suggest that the
epidemiology of longitudinal telomere dynamics is fundamentally
distinct from the epidemiology of cross-sectional telomere length.
Although many variables may be associated with cross-sectional
telomere length at a single time point, reflecting the cumulative
lifetime burdens of genetic and environmental exposures, most of
these effects appear to be dwarfed by the apparent negative
feedback from baseline telomere length to telomere trajectory.
Moreover, confounding by measured or unmeasured factors, may
have contributed to associations of lifestyle factors with cross-
sectional telomere length in previous studies.
In this study of individuals with established coronary artery
disease, increasing age and male sex were associated with
accelerated telomere attrition, even after accounting for differenc-
es in baseline telomere length. These findings conflict with prior
Table 1. Baseline characteristics of study population categorized by trajectory of leukocyte telomere length over five years.
VARIABLE Shortened N=276 Maintained N=192 Lengthened N=140 P
Age 67611 65610 66610 0.39
Male (%) 241(87) 145(76) 113(81) 0.004
Baseline Telomere Length (T/S) 1.0660.19 0.8660.15 0.7160.14 ,0.001
Ethnicity (%) 0.20
- Hispanic 20 (7) 19 (10) 19 (14)
- Asian 28 (10) 26 (14) 19 (14)
- Black 55 (20) 26 (14) 17 (12)
- White 167 (61) 115 (60) 80 (57)
- Other 6 (2) 6 (3) 5 (4)
Education . High School (%) 199(72) 137(71) 108(77) 0.49
Income $ $50000 (%) 56(20) 49(26) 32(23) 0.1
Hypertension (%) 200(73) 130(68) 95(68) 0.45
Prior MI (%) 146(53) 93(48) 78(56) 0.39
Prior CHF (%) 44(16) 26(14) 20(15) 0.77
Prior Stroke (%) 30(11) 23(12) 22(16) 0.35
Type II Diabetes (%) 62(22) 49(26) 35(24) 0.71
Prior Revascularization (%) 175(63) 121(64) 70(50) 0.02
Current Smoking (%) 50(18) 26(14) 25(18) 0.38
Past Smoking (%) 144(52) 95(50) 68(49) 0.74
LVEF 0.6360.09 0.6260.09 0.6160.09 0.06
BMI 2865.1 2865.0 2965.4 0.56
Waist-to-hip ratio 0.9660.08 0.9460.08 0.9560.08 0.003
Physically Active (%) 190(69) 131(69) 90(64) 0.59
Exercise Capacity (Mets) 8.163.2 8.163.1 7.563.4 0.19
Statin use (%) 187(68) 140(73) 96(69) 0.47
Beta-blocker use (%) 161(58) 113(59) 77(55) 0.75
ACE/ARB use (%) 140(51) 100(52) 69(49) 0.88
Aspirin use (%) 227(82) 147(77) 101(72) 0.05
Vitamin use (%) 73(27) 31(16) 24(17) 0.01
Log Fasting Glucose 4.760.2 4.760.3 4.760.2 0.85
Log HDL 3.860.3 3.860.3 3.860.3 0.27
Log LDL 4.660.3 4.660.3 4.660.3 0.14
Log CRP 0.5861.3 0.5461.3 0.6061.3 0.89
Log Insulin 5.660.7 5.760.6 5.760.5 0.30
Log TNF-alpha 1.260.8 1.261.0 1.160.9 0.71
Log IL-6 0.960.7 0.860.7 0.960.7 0.61
Log Adiponectin 16.860.8 16.960.8 16.860.7 0.55
Log Leptin 8.961.1 9.061.0 9.161.1 0.18
doi:10.1371/journal.pone.0008612.t001
Telomere Length Trajectory
PLoS ONE | www.plosone.org 4 January 2010 | Volume 5 | Issue 1 | e8612
studies of healthy individuals, which have reported no significant
independent effect of sex[18], and a bimodal effect of increasing
age[28]. Further studies are needed to examine the effects of age
and gender on telomere maintenance and telomerase activity in
persons with and without cardiovascular disease.
The association of obesity with short telomere length has been
observed [13,29], but the effects of body mass index and waist-to-
hip ratio on telomere dynamics have not been previously reported.
We found no independent association of body mass index with
telomere trajectory, suggesting that the biological effect is driven
primarily by abdominal obesity. Furthermore, we observed no
attenuation of this association after adjustment for adipokines and
systemic inflammatory mediators that are typically associated with
abdominal obesity. Indeed, abdominal obesity appeared to have
an even stronger effect on telomere shortening after adjusting for
these variables.
Oxidative stress may provide a potential link between
abdominal obesity and telomere shortening. Epidemiologic studies
have demonstrated a robust association between abdominal
obesity and oxidative stress[30]. Excess production of free radicals
causes premature cellular senescence and accelerates age-associ-
ated tissue damage in animal models of visceral obesity[31].
Moreover, oxidative stress directly exerts a negative effect on
telomere length maintenance, both through inhibition of telome-
rase activity[32] and direct erosion of GGG triplets in telomeric
DNA[33]. Further studies are warranted to elucidate the
mechanisms whereby abdominal obesity accelerates telomeric
aging in vivo.
Figure 1. Distributions of baseline and follow-up leukocyte
telomere length.
doi:10.1371/journal.pone.0008612.g001
Figure 2. Distribution of leukocyte telomere attrition rate (base
pairs per year).
doi:10.1371/journal.pone.0008612.g002
Figure 3. Scatterplot of change in telomere length against
baseline telomere length (r = 0.76; p,0.0001).
doi:10.1371/journal.pone.0008612.g003
Table 2. Independent predictors of change in leukocyte
telomere length as a continuous variable (multivariable linear




(base pairs/year) 95% CI P value
Baseline Telomere Length (T/S) 2151 2302, +1 0.05
Baseline Telomere Length (T/S)2 2108 2185, 230 0.007
Age (per 10 yrs) 216 221, 211 ,0.001
Male 225 240, 210 0.001
Waist-to-hip ratio 286 2156, 216 0.02
Final model also adjusted for ethnicity and LVEF.
doi:10.1371/journal.pone.0008612.t002
Table 3. Independent predictors of leukocyte telomere
shortening as a dichotomous variable (multivariable logistic




Telomere Shortening 95% CI P value
Baseline T/S (per SD) 7.6 5.5, 10.6 ,0.001
Age (per 10 yrs) 1.6 1.3, 2.1 ,0.001
Male 2.4 1.3, 4.7 0.007
Waist-to-hip ratio (per 0.1 increase) 1.4 1.0, 2.0 0.04
Final model also adjusted for ethnicity and LVEF.
doi:10.1371/journal.pone.0008612.t003
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No cardioprotective medications were found to have an
independent effect on telomere trajectory. In particular, we found
no association of statin use with change in telomere length. These
findings support and extend the prior observation that, while
statins attenuate the excess risk of coronary events conferred by
short telomeres, their use is not associated with longer telo-
meres[7].
Among the strengths of the present study is the measurement of
a wide range of candidate variables that have been associated with
telomeric aging. The longitudinal study design allowed us to
identify the determinants of leukocyte telomere trajectory in a
large cohort of patients with stable coronary artery disease.
However, several limitations should be considered in the
interpretation of our results. First, our measurements were
restricted to telomere length in circulating leukocytes and do not
necessarily reflect telomere trajectory in other cell compartments
such as myocardium, endothelium, or the atherosclerotic plaque.
Second, the quantitative PCR technique employed in this study
measures the mean telomere length across all chromosomes
present in the participant’s blood sample. However, evidence from
rodents suggests that the shortest telomere, rather than the mean
telomere length, may be the more important determinant of cell
viability and chromosomal stability[34]. As such, our use of mean
telomere length could have resulted in a loss of precision with
regard to ascertainment of the shortest telomere length in each
cell. Third, we were not able to perform assays of telomerase
activity, which might further clarify the mechanisms of telomere
lengthening in a subset of patients. Fourth, our evaluation of
abdominal obesity was based on waist-to-hip ratio, but more
sophisticated imaging techniques such as computed tomography
would likely provide more accurate classification in this regard.
Fifth, the study sample consisted only of individuals with
established coronary artery disease. As such, our findings may
not be applicable to healthy individuals, and we are not able to
directly estimate the effect of coronary artery disease on the rate of
telomere length change.
Finally, as with any repeated measurement of a continuous
variable, the possibility of regression to the mean should be
considered. This is however extremely unlikely, because baseline
telomere length was not used as an inclusion criterion. Indeed,
each and every participant with baseline and follow-up telomere
measurements was included in the study. Moreover, we measured
baseline and follow-up telomere length in duplicate or triplicate for
every sample, thereby limiting the effects of random fluctuation
due to test conditions. The coefficients of variability achieved
approach those of the Southern blot technique, which remains the
gold standard for telomere length assessment.
In summary, we report that leukocyte telomere trajectory in a
cohort of persons with coronary artery disease is powerfully
influenced by baseline telomere length in a pattern suggestive of
negative feedback regulation. Age, male sex, and abdominal
obesity also independently predicted telomere shortening. Future
studies will further elucidate the mechanisms, significance, and
reversibility of telomeric aging in cardiovascular disease.
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